KemPharm, Inc. (KMPH) Financial Analysis & Valuation | Quarter Chart
KemPharm, Inc. (KMPH)
KMPHPrice: $5.81
Fair Value: 🔒
🔒score
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to ge... more
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodr... more
Description
Shares
| Market Cap | $200.47M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Richard W. Pascoe |
| IPO Date | 2015-04-16 | CAGR | — |
| Employees | 24 | Website | kempharm.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KMPH chart loading...
Fundamentals
Technicals
| Enterprise Value | $244.89M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 5.5 | P/B Ratio | 3.23 |
| P/CF Ratio | 52.02 | P/FCF Ratio | 56.03 |
| EPS | $-0.91 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 222.55% | Gross Margin | 0.86% |
| Operating Margin | -0.4% | Profit Margin | 1.02% |
| ROE | 0.81% | ROA | 0.45% |
| ROCE | -0.21% | Current Ratio | 4.89 |
| Quick Ratio | 4.84 | Cash Ratio | 2.03 |
| Debt/Equity | 0.01 | Interest Coverage | -11.34 |
| Altman Z Score | 0.88 | Piotroski Score | 7 |